Optimal treatment approach continues to remain a challenge for systemic light chain amyloidosis (AL). So far, Auto-SCT is the only modality associated with long-term survival. However, failure to show survival benefit in randomized study raises questions regarding its efficacy. We present a comparative outcome analysis of Auto-SCT to conventional therapies (CTR) in AL patients treated over a 14-year period at our institution. Out of the 145 AL amyloidosis patients, Auto-SCT was performed in 80 patients with 1-year non-relapse mortality rate of 12.5%. Novel agents were used as part of induction therapy in 56% of transplant recipients vs 46% of CTR patients. Hematological and organ responses were seen in 74.6% and 39% in the Auto-SCT arm vs 53% and 12% in the CTR arm, respectively. The projected 5-year survival for Auto-SCT vs CTR was 63% vs 38%, respectively. Landmark analysis of patients alive at 1-year after diagnosis showed improved 5-year OS of 72% with Auto-SCT vs 65% in the CTR arm. In the multivariate analysis, age o60 years, induction therapy with novel agents, kidney only involvement and Auto-SCT were associated with improved survival. In conclusion, Auto-SCT is associated with long-term survival for patients with AL amyloidosis.
INTRODUCTION
Light chain amyloidosis (AL) is a clonal plasma cell disorder with extracellular deposition of fibril forming light chains and can be seen in association with other plasma cell dyscrasias, including multiple myeloma and Waldenstrom macroglobulinemia. 1 The therapeutic armamentarium for AL amyloidosis has greatly expanded since 1997 2 , when melphalan-prednisone based therapy was the only available option. Today, there are several effective therapies, including high-dose dexamethasonebased regimens 3 combined with melphalan, 4 thalidomide, 5 cyclophosphamide-thalidomide, 6 lenalidomide, 7, 8 bortezomib, 9, 10 as well as high-dose melphalan followed by Auto-SCT. [11] [12] [13] [14] Thus far, Auto-SCT is the only modality that has been associated with improved long-term outcomes in AL amyloidosis. 12, 13, 15, 16 . When careful patient selection is performed, even the patients with cardiac involvement have benefitted from Auto-SCT. 16 However, the French Myeloma Collaborative Group compared melphalandexamethasone combination therapy with Auto-SCT in a randomized trial and found no significant differences in hematological or organ response, and a landmark analysis examining only those patients surviving ⩾ 6 months after transplant also showed no survival advantage for Auto-SCT. 14 The major limitations of that trial were a high incidence of non-relapse mortality (24%) and a reduced dose of melphalan (140 mg/m 2 ) in almost 25% of the patients. This remained a major criticism as a more recent study has shown that reduced doses of melphalan in conditioning regimens are also associated with poor outcomes. 16, 17 In a metaanalysis of 12 studies analyzing treatment modalities for AL amyloidosis, no survival benefit was reported for patients receiving Auto-SCT. 18 However, the analysis was limited by incomplete data and inclusion of small studies.
Because of these conflicting results, there is a need for longterm follow-up study of AL amyloidosis patients undergoing different therapeutic modalities and re-examine the role of highdose chemotherapy in the treatment of AL. 19, 20 Therefore, we performed a retrospective chart analysis of AL amyloidosis patients being treated at our institution and compared survival outcomes of Auto-SCT vs conventional treatments (CTR).
PATIENTS AND METHODS

Patient selection
We systematically reviewed all pathology cases that carried the term amyloidosis in their descriptions between the period 1998 and 2011. Selected cases were further confirmed for the diagnosis of AL as shown by Congo red staining with the concomitant plasma cell clonality established by serum free light chain studies (when available) and serum and urine immunofixation, in conjunction with BM immunohistochemistry (CD138, kappa and lambda). Confirmed cases were included in the retrospective chart review on an institutional review board-approved protocol.
AL amyloidosis
Using International Myeloma Working Group criteria, 21, 22 systemic AL amyloidosis was defined as the presence of an amyloid-related systemic disease (for example, renal, liver, heart, gastrointestinal or peripheral nerve involvement). To be included as diagnostic criterion, the organ damage had to be related to amyloid deposition and not to another common disease, such as diabetes or hypertension. Positive amyloid staining by Congo red in any tissue (for example, fat aspirate, BM aspirate or organ biopsy) was considered a definitive sign of amyloidosis.
Assessment of cardiac involvement
We systematically reviewed data on cardiac biomarkers, including brain natriuretic peptide, N-terminal of the prohormone brain natriuretic peptide, Troponin-I (>0.03), Troponin-T (>0.01), intra-ventricular septal thickness (>1.2 cm) and left ventricular ejection fraction (o45%), on two-dimensional echocardiography as well as cardiac biopsy confirming amyloid deposits, when available.
Transplantation details
All patients received a melphalan-based conditioning regimen. The choice and dose of a patient's conditioning regimen was based on the patient's performance status and the treating physician's judgment.
Response and progression
Hematological responses were scored according to the uniform response criteria for AL amyloidosis. 21 CR was defined as BM with o 5% plasma cells and negative immunofixation of the serum and urine and normal free light chain ratio. PR was a 50% reduction in serum or urine M-protein, or if serum M-protein o0.5 g/dL, 50% reduction in serum and urine light chain. Progression disease (PD) was defined as any detectable monoclonal protein or abnormal light chain ratio in a patient with CR or a 50% increase in serum or urine monoclonal protein for a patient in PR. Stable disease (SD) was defined as the absence of CR, PR or PD.
Organ response was defined according to the published guidelines as per the Tenth International Symposium on Amyloidosis. 21 
Statistical analysis
The two-sided Fisher's exact test was used to test for differences between categorical variables. We used the product limit estimator of Kaplan and Meier to estimate OS and log rank statistics to compare the groups. 23 We measured OS from the date of diagnosis of AL amyloidosis. Factors evaluated for their impact on OS included: Auto-SCT vs CTR; cardiac involvement, renal involvement, age ⩾ 60 years, involvement of ⩾ 2 organs, receiving of induction therapy and treatment with novel agents. We also compared the impact of Auto-SCT in patients alive at 1 year after diagnosis. The Cox proportional hazard model was used to perform multivariate analyses of possible prognostic variables for OS. All statistical analysis was conducted using the SPSS 12.0 statistical software (IBM, Armonk, NY, USA). A P-valueo0.05 was considered to be statistically significant.
RESULTS
Patient characteristics
A total of 145 AL patients were seen at MDACC between a period of January 1998 and August 2011, where 80 patients underwent Auto-SCT. Baseline patient characteristics are listed in Table 1 . The median age at diagnosis for the whole cohort was 59 years (range, 33-87 years) and the median follow-up for the whole cohort was 3 years. The distribution of various induction regimens in the Auto-SCT and CTR arms are shown in Table 1 . When compared with the CTR arm, a significant bias towards a favorable distribution was seen in the Auto-SCT arm for the following parameters: age (P = 0.0001); ⩾ 2 organ involvement (P = 0.03); cardiac involvement (P = 0.0001); serum creatinine ⩾ 2.5 mg/dL (P = 0.04); BM plasma cells ⩾ 10% (0.006); hemoglobino10 g/dL (P = 0.04), and left ventricular ejection fractiono50% (P = 0.03). Auto-SCT patient characteristics, including cardiac staging and renal involvement, are described in Table 2 . There were three patients who underwent attempted mobilization but did not complete the process and did not receive Auto-SCT. They were grouped under the CTR arm.
Hematological response A total of 18 patients (28%) in the CTR arm received no treatment at all and were excluded from the response calculations. Utilization of a novel drug in the induction therapy was 56% in the Auto-SCT vs 46% in the CTR arm (P = 0.4). The distribution of the hematological response in the CTR arm was: CR = 6 (13%); PR = 19 (40%); SD = 2 (4%); and PD = 17 (36%). Among the patients undergoing Auto-SCT, 16 patients did not receive any treatment before transplant. The distribution of the hematological response in the Auto-SCT arm before transplant was: CR = 8 (12.5%); PR = 33 (51.5%); SD = 18 (28%); and PD = 3 (5%). There were five early deaths and were excluded from the post-transplant response calculations. The hematological response distribution in the posttransplant setting was: CR = 14 (18.6%); PR = 42 (56%); and SD = 15 (20%). The overall hematological response ⩾ PR was significantly higher in the Auto-SCT arm when compared with the CTR arm (75% vs 53%; P = 0.001).
Organ response When compared with Auto-SCT arm, a higher number of patients in the CTR arm had cardiac involvement (23 vs 48%; P = 0.0001) 
Survival
The median follow-up was 3 years for the whole cohort and the median overall survival was 6.5 years, with estimated 5-year survival of 53% and 10-year survival of 35% for the whole cohort. Early death as defined by occurrence within 100 days of initial presentation was seen in 12 patients in the CTR arm as compared with 1 patient in the Auto-SCT arm (P = 0.007). Specifically for the Auto-SCT patients, 6 patients (7.5%) died within the first 100 days of transplant and 10 patients (12.5%) died within 1 year post transplant, without evidence of PD. When comparing Auto-SCT to CTR arm, the estimated 5-year survival was 63% vs 38% (P = 0.0001) and 10-year survival was 56% vs 10% (P = 0.0001) (Figure 1a) . In the univariate analysis, the following additional factors were associated with improved OS: o2 organ involvement (5-year OS: 64% vs 40%; P = 0.03) ( Figure 1b) ; kidney only involvement (5-year OS: 76% vs 41%; P = 0.008) ( Figure 1c) ; no cardiac involvement (5-year OS: 62% vs 38%; P = 0.011) ( Figure 1d) ; age o60 years at diagnosis (5-year OS: 61% vs 45%; P = 0.002) ( Figure 1e) ; and inclusion of novel agents in induction regimen (67% vs 43%; P = 0.05) (Figure 1f) .
In the multivariate analysis; age o 60 years (P = 0.01), induction therapy with novel agents (P = 0.04); kidney only involvement (P = 0.04) and Auto-SCT (P = 0.004) were associated with improved survival.
When evaluating only those patients with overt cardiac involvement with or without other organ involvement (n = 49), Auto-SCT led to significant improvement in OS (5-year OS: 51% vs 37% P = 0.03). In the patient cohort with kidney as the only organ affected by amyloidosis (n = 53), improvement in OS was seen with Auto-SCT (5-year OS: 82% vs 58%; P = 0.01). As greater disease burden and end organ damage adds to the mortality risk associated with Auto-SCT, we analyzed all patients with documented involvement of ⩾ 2 organs (n = 59) and again found improved outcomes with Auto-SCT (5-year OS: 45% vs 36%; P = 0.02).
Patients at 1-year post diagnosis. We recognize that because of the retrospective nature of our analysis, there may have been selection bias, with healthier patients aggregated in the Auto-SCT arm and those with higher numbers of comorbidities deemed ineligible for transplantation based on their presentation and higher disease burden, in the CTR arm. Therefore, we specifically evaluated patients who were alive at 1 year after their initial diagnosis (Auto-SCT = 69; CTR = 31) and discovered improved OS with Auto-SCT (5-year OS: 72% vs 65% for the CTR arm, P = 0.008).
Age >60 years. As a higher proportion of older patients was seen in the CTR arm, we specifically analyzed patients aged >60 years at the time of diagnosis (Auto-SCT = 29; CTR = 40). Among this group, Auto-SCT was associated with improved survival (5-year OS 59% vs 34%; P = 0.005).
Patients undergoing induction therapy. A total of 111 patients received some form of induction therapy, with 80% of patients in the Auto-SCT arm receiving at least one treatment cycle, compared with 72% in the CTR arm (P = 0.3). However, 27% patients in the CTR arm did not get any therapy at all. In order to eliminate this bias, we evaluated the effect of Auto-SCT in AL amyloidosis patients who received any type of induction treatment (Auto-SCT = 64; CTR = 47). The same proportion of patients in both arms received novel agents. Again, Auto-SCT was associated with a significantly higher 5-year OS (68% vs 37%; P = 0.0001). Seventy-five patients received induction therapy consisting of novel agents. Within this subset also, Auto-SCT was associated with improved survival (5-year OS: 84% vs 39%; P = 0.0001). We performed additional analysis within the subset of Auto-SCT patients and found a trend towards improved survival for patients receiving any induction therapy (5-year OS: 37% vs 68%; P = 0.06). Out of the 111 patients who received any treatment, response data were missing in 5 patients. We specifically analyzed the effect of Auto-SCT in patients achieving more than a PR. These patients had a median follow-up of 4 years and showed improved OS with Auto-SCT (5-year OS: 69% vs 64%; P = 0.05). As the year of diagnosis of AL amyloidosis may have also impacted the overall outcomes owing to the emergence of novel therapies as well as newer diagnostic modalities, we specifically analyzed the effect of Auto-SCT in patients treated after the year 2004 (Auto-SCT = 59; CTR = 43) and found similar improvement in OS (5-year OS: 72% vs 33%; P = 0.05).
DISCUSSION
With a maximum follow-up of 14 years for the surviving AL amyloidosis patients, we report that Auto-SCT is associated with significantly improved OS compared with CTR. One of the major limitations of our study is the retrospective nature of analysis over a long period of time as well as analysis of data in a nonrandomized fashion. We have performed landmark analysis and subset analyses to try to overcome these biases.
Consistent with published reports, cardiac involvement by itself was associated with poor survival. 24 Wechelakar et al. 25 recently reported a median survival of only 7 months for stage III cardiac amyloidosis patients treated with non-transplant modalities. In our study, a significantly higher number of patients with cardiac involvement did not proceed to Auto-SCT, which may have contributed to an improved survival with transplantation. However, to avoid that potential bias, we specifically compared the outcome of patients with cardiac AL between the two treatment groups. We were able to demonstrate improved survival with Auto-SCT in the subset of cardiac amyloidosis patients. Although we had a limited number of patients, our findings were consistent Abbreviations: BNP = brain natriuretic peptide; IVS = intra-ventricular septal; LVEF = left ventricular ejection fraction; NT Pro-BNP = N-terminal of the prohormone brain natriuretic peptide.
Auto-SCT in AL S Parmar et al with a recent study of 187 cardiac amyloidosis patients undergoing Auto-SCT in which a median survival of 66 months was reported. 16 Unfortunately, because of the retrospective nature of our study and the long time period involved, we did not have the availability of cardiac biomarkers for a majority of our patients, especially in the non-transplant arm. In fact, we may have underestimated the cardiac involvement in our patients as they were selected based on their clinical parameters, including poor left ventricular ejection fraction, increased intra-ventricular septal thickness and biopsy-proven cardiac amyloidosis. Usually, symptomatic cardiac amyloidosis is associated with high non-relapse mortality and increased morbidity with high-dose therapy. However, in our retrospective analysis, the estimated 5-year survival of 51% with Auto-SCT in this high-risk population is very promising. Lower non-relapse mortality and improved survival underscore the importance of Auto-SCT in overcoming the poor prognosis associated with cardiac amyloidosis. 26 An increased understanding of cardiac amyloidosis and systematic collection of serum cardiac biomarkers will aid in the risk stratification of individual patients and allow for better patient selection that may overcome the initial mortality and morbidity in these patients. 24, [27] [28] [29] Higher burden of disease, as evidenced by involvement of ⩾ 2 organs, was also associated with poor survival. 21 The poor survival of these patients may be related to the prevalence of cardiac involvement in this group. Because of the retrospective nature of our analysis and failure to capture the extent of organ involvement, especially in the cases treated outside of our institution, we may have underestimated the patients' disease burden. However, our results are consistent with the published literature and emphasize the importance of identifying these patients for early intervention. 9 When analyzing this subset of patients with high disease burden, we were able to demonstrate a significant improvement in OS associated with Auto-SCT. Earlier intervention and incorporation of novel agents before transplant as well as part of the conditioning regimen may further improve morbidity and PD rates. 30 Practicing physicians are generally reluctant to offer Auto-SCT to AL amyloid patients aged >60 years. In our study, Auto-SCT was found to be beneficial for older patients. Our results are consistent with those reported by Seldin et al., 31 who reported comparable results in terms of toxicity, hematological remission rate and survival in 65 older patients and 280 younger patients after Auto-SCT.
An unexpected finding in our study was a relatively low rate of hematological CR of 19% after an auto-HCT. In previous studies from various centers, a CR rate of 27-40% has been reported. Although it is difficult to identify the exact reason for this lower CR rate, it may be due to a high disease burden and unavailability of immunofixation studies and light chain analysis in some patients, which are essential to define a CR.
Because the outcome of AL amyloidosis patients is heterogeneous, nearly 40% mortality rate is observed in the first year of diagnosis owing to advanced organ involvement. 32 During the first year of diagnosis, 34 patients in the conventional therapy arm and 11 patients in the transplant arm died. In order to overcome this bias, we specifically demonstrated improved survival with Auto-SCT among patients alive at 1 year after their initial diagnosis.
Because of the retrospective nature of our analysis, we were not able to capture all the treatments received by the patients, especially in the non-transplant arm. In our subset analyses of patients who underwent at least one cycle of myeloma-directed therapy, a significant improvement in survival was noted in patients receiving Auto-SCT. Furthermore, a hematological response of greater than a PR as well as patients receiving induction therapy consisting of novel agent also benefitted with the Auto-SCT modality. By performing these subset analyses, we have tried to overcome some of the shortcomings inherent in retrospective studies, especially related to the poor patient population in the CTR arm. We believe that the low non-relapse mortality at our center may be due to better patient selection, improved supportive care and incorporation of novel therapeutic agents in the induction therapy. Similar improvement in outcomes has also been reported from other centers. 33, 34 One of the major challenges to adopting Auto-SCT as an upfront strategy for primary amyloidosis patients is their disease burden and significant comorbidities, which precludes them from undergoing aggressive therapy. In fact, for all the newly diagnosed AL patients, only approximately 20% of patients are able to undergo Auto-SCT. 35 With the incorporation of novel agents like bortezomib 30 and lenalidomide-based therapies, 36 we believe that high rates of hematological responses and improved organ function may expand the number of transplant eligible patients. The approach to these patients should be multidisciplinary, with early referral to a cardiologist for detailed cardiac assessment, including endomyocardial biopsy, where indicated, as well as optimization of cardiac function by judicious use of diuretics and other interventions. Careful monitoring of fluid status during the mobilization process involving high-dose granulocyte colonystimulating factor remains a critical component to control for patient morbidity and ensure successful outcomes. At our center, AL amyloidosis patients with cardiac involvement are mobilized as inpatients to monitor for arrhythmia and fluid balance to minimize the risk of sudden death. Furthermore, Auto-SCT should preferably be performed at institutions with experience and high volumes of amyloidosis patients.
We believe that, with better risk stratification, incorporation of novel agents in the pretransplant and post-transplant treatment strategy and improved patient selection, we can improve outcomes for patients suffering from AL amyloidosis. We conclude that Auto-SCT therapy is associated with improved outcomes in AL amyloidosis patients, and its role should be evaluated in prospective studies in this era of novel therapeutics.
